Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Information source: Mahidol University
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Strongyloidiasis
Intervention: albendazole (Drug); Ivermectin (Drug); ivermectin (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Mahidol University Official(s) and/or principal investigator(s):
Yupin Suputtamongkol, MD, Principal Investigator, Affiliation: Faculty of Medicine, Siriraj Hospital, Mahidol University
Overall contact:
Yupin Suputtamongkol, MD, Phone: 66 2 4197203, Email: siysp@mahidol.ac.th
Summary
A prospective controlled trial to compare the efficacy and safety of 7-day albendazole,
single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic
strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.
Clinical Details
Official title: Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: cure rate
Secondary outcome: safety
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with positive strongyloides larva in the stool
Exclusion Criteria:
- Pregnancy
- Lactating women
- Known allergy to any study drug
Locations and Contacts
Yupin Suputtamongkol, MD, Phone: 66 2 4197203, Email: siysp@mahidol.ac.th
Siriraj Hospital, Bangkoknoi, Bangkok 10700, Thailand; Recruiting
Yupin Suputtamongkol, MD, Phone: 66 2 419 7203, Email: siysp@mahidol.ac.th
Darawan Wanachewanawin, MD, Sub-Investigator
Surasak Nilganuwong, MD, Sub-Investigator
Thanomsak Aekthananon, MD, Sub-Investigator
Nalinee Premasathian, MD, Sub-Investigator
Ekapun Karooponge, MD, Sub-Investigator
Kid Bhumimuang, MD, Sub-Investigator
Chanikarn Kanaderm, MD, Sub-Investigator
Additional Information
Starting date: July 2008
Ending date: December 2009
Last updated: September 30, 2008
|
